TriSalus CCO receives 561 ESPP shares
TriSalus Life Sciences, Inc. Chief Commercial Officer Richard Marshak acquired 561 shares of common stock at $3.8700 per share.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
TriSalus Life Sciences, Inc. Chief Commercial Officer Richard Marshak acquired 561 shares of common stock at $3.8700 per share. The shares were obtained through the company’s Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3. Following this award, he directly holds 128,319 shares.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 561 | $3.87 | $2K |
Footnotes (1)
- F1. Represents shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3.
Key Figures
Key Terms
Employee Stock Purchase Plan financial
Rule 16b-3 regulatory
grant/award acquisition financial
common stock financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did TriSalus Life Sciences (TLSI) disclose in this Form 4 for Richard Marshak?
What are Richard Marshak’s total TriSalus (TLSI) holdings after this transaction?
Does the Form 4 indicate if Richard Marshak’s TriSalus (TLSI) holdings are direct or indirect?
AI-generated analysis. How Rhea-AI works. Not financial advice.